BRPI0710054B8 - métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste - Google Patents

métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste

Info

Publication number
BRPI0710054B8
BRPI0710054B8 BRPI0710054A BRPI0710054A BRPI0710054B8 BR PI0710054 B8 BRPI0710054 B8 BR PI0710054B8 BR PI0710054 A BRPI0710054 A BR PI0710054A BR PI0710054 A BRPI0710054 A BR PI0710054A BR PI0710054 B8 BRPI0710054 B8 BR PI0710054B8
Authority
BR
Brazil
Prior art keywords
test compound
methods
identifying
testing
screening
Prior art date
Application number
BRPI0710054A
Other languages
English (en)
Inventor
G Cezar Gabriela
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0710054A2 publication Critical patent/BRPI0710054A2/pt
Publication of BRPI0710054B1 publication Critical patent/BRPI0710054B1/pt
Publication of BRPI0710054B8 publication Critical patent/BRPI0710054B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste e para testar um composto de teste, e, perfil de biomarcador para identificar um composto de teste como um composto tóxico. a invenção provê perfis de biomarcador de metabólitos celulares e métodos para triar compostos químicos incluindo agentes farmacêuticos, compostos de fármacos de ponta e candidatos e outros produtos químicos usando células-tronco embriônicas humanas (hesc) ou células específicas de linhagem produzidas a partir das mesmas. os métodos da invenção são utilizáveis para testar a toxicidade, particularmente toxicidade desenvolvimental, e detectar os efeitos teratogênicos destes compostos químicos.
BRPI0710054A 2006-04-10 2007-04-10 métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste BRPI0710054B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79064706P 2006-04-10 2006-04-10
US60/790,647 2006-04-10
US60/790647 2006-04-11
US82216306P 2006-08-11 2006-08-11
US60/822,163 2006-08-11
US60/822163 2006-08-11
PCT/US2007/008923 WO2007120699A2 (en) 2006-04-10 2007-04-10 Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals

Publications (3)

Publication Number Publication Date
BRPI0710054A2 BRPI0710054A2 (pt) 2011-08-02
BRPI0710054B1 BRPI0710054B1 (pt) 2020-11-17
BRPI0710054B8 true BRPI0710054B8 (pt) 2021-07-27

Family

ID=38515874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710054A BRPI0710054B8 (pt) 2006-04-10 2007-04-10 métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste

Country Status (11)

Country Link
US (2) US8703483B2 (pt)
EP (1) EP2013619B1 (pt)
JP (2) JP5421767B2 (pt)
BR (1) BRPI0710054B8 (pt)
CA (1) CA2648218C (pt)
DK (1) DK2013619T3 (pt)
GB (1) GB2451042A (pt)
HU (1) HUE036378T2 (pt)
MX (1) MX2008013002A (pt)
SE (2) SE1050445A1 (pt)
WO (1) WO2007120699A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007304423A1 (en) * 2006-10-02 2008-04-10 Cellartis Ab Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells
WO2008097491A2 (en) * 2007-02-05 2008-08-14 Wisconsin Alumni Research Foundation Biomarkers of ionizing radiation response
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US8901487B2 (en) * 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
US20120088679A1 (en) * 2009-03-10 2012-04-12 Bayer Healthcare Llc Method for Monitoring Cell Culture
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
US20110081675A1 (en) * 2009-10-06 2011-04-07 Wisconsin Alumni Research Foundation Metabolic Biomarkers Of Drug-Induced Cardiotoxicity
US20120209535A1 (en) * 2009-10-21 2012-08-16 Basf Plant Science Company Gmbh Method for generating biomarker reference patterns
US8703424B2 (en) 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
WO2011139914A1 (en) * 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
AU2011329002C1 (en) 2010-11-15 2017-05-25 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US8829426B2 (en) 2011-07-14 2014-09-09 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
US9164106B2 (en) * 2012-03-15 2015-10-20 Greenwood Genetic Center, Inc. Determination of decreased metabolism of tryptophan in diagnosis of autism spectrum disorders
DK2914748T3 (da) * 2012-11-02 2019-06-11 Stemina Biomarker Discovery Inc Forudsigelse af udviklingen af toxicitet af farmaceutika for mennesker, under anvendelse af humane stamcellelignende celler og metaboliske forholdstal
EP2925860B8 (en) 2012-11-30 2019-12-25 Accelerated BioSciences Corp. Methods of differentiating stem cells by modulating mir-124
US20160146789A1 (en) * 2013-07-03 2016-05-26 Coyne Scientific, Llc Methods for Predicting Responses to Chemical or Biological Substances
GB2548059B (en) 2014-11-26 2020-09-02 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
GB201519186D0 (en) * 2015-10-30 2015-12-16 Electrophoretics Ltd Isotopic methods for measurement of tryptophan and metabolites thereof
WO2018157004A1 (en) * 2017-02-24 2018-08-30 Coyne Scientific, Llc Methods for determining the incidence and/or intensity of effects of a chemical or biological agent on members of a target population using stem cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102083408B1 (ko) * 2017-04-28 2020-03-02 가천대학교 산학협력단 줄기세포 기반의 독성 물질 스크리닝 방법
WO2020232436A1 (en) 2019-05-16 2020-11-19 Brown University A human in vitro cardiotoxicity model
CN115697969B (zh) * 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
US12504423B2 (en) 2020-10-16 2025-12-23 Brown University Human in vitro cardiotoxicity model
US12076437B2 (en) 2021-07-12 2024-09-03 Brown University Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue
US20250246259A1 (en) 2022-03-30 2025-07-31 Infinite D.O.O. Method for predictive testing of agents to assess triggering and suppressing adverse outcomes and/or diseases
CN121136913B (zh) * 2025-11-17 2026-04-03 杭州艾名医学科技有限公司 一种肠类器官模型体外评价药物肠毒性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JPH11225795A (ja) 1998-02-13 1999-08-24 Oriental Yeast Co Ltd 細胞障害マーカー
EP1064353B1 (en) * 1998-03-18 2002-11-06 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
AU2001266650A1 (en) * 2000-06-02 2001-12-17 Large Scale Proteomics Corp Protein markers for pharmaceuticals and related toxicity
US6680203B2 (en) * 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
EP1176189A1 (en) * 2000-07-21 2002-01-30 Fornix Biosciences N.V. Stem cell-like cells
EP1362911A4 (en) * 2001-02-23 2005-01-05 Mitsubishi Chem Corp ENZYMGEN OF THE MEDICAMENT METABOLISM TRANSGENIC ANIMAL AND USE THEREOF
WO2003005628A2 (en) 2001-07-06 2003-01-16 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
US20030224345A1 (en) * 2001-08-24 2003-12-04 Advanced Cell Technology Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
US20030232430A1 (en) * 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US6982152B2 (en) 2002-04-17 2006-01-03 Promega Corporation Cytotoxicity assay
US20040121305A1 (en) * 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
ATE439039T1 (de) * 2003-01-16 2009-08-15 Gen Hospital Corp Verwendung von dreidimensionalen, mikrogefertigten, mittels gewebetechnologie hergestellten systemen für pharmakologische anwendungen
JP2005022096A (ja) 2003-06-30 2005-01-27 Three M Innovative Properties Co 遮光性装飾シート
EP1644485B9 (en) * 2003-07-08 2012-01-04 Axiogenesis Ag Secreted proteins as markers for cell differentiation
US8148152B2 (en) 2003-07-08 2012-04-03 Axiogenesis Ag Method for the preparation of embryoid bodies (EBs) and uses thereof
WO2005080551A2 (en) 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
JP5074921B2 (ja) 2004-04-07 2012-11-14 アキシオジェネシス エージー 非侵襲性生体外機能組織検定システム

Also Published As

Publication number Publication date
WO2007120699A2 (en) 2007-10-25
CA2648218C (en) 2015-06-02
EP2013619A2 (en) 2009-01-14
BRPI0710054B1 (pt) 2020-11-17
US20140255969A1 (en) 2014-09-11
JP5421767B2 (ja) 2014-02-19
US8703483B2 (en) 2014-04-22
MX2008013002A (es) 2008-10-17
WO2007120699A3 (en) 2008-01-24
JP2013078342A (ja) 2013-05-02
DK2013619T3 (en) 2017-12-04
CA2648218A1 (en) 2007-10-25
SE1050445A1 (sv) 2010-05-04
US20070248947A1 (en) 2007-10-25
JP2009533056A (ja) 2009-09-17
GB0820454D0 (en) 2008-12-17
BRPI0710054A2 (pt) 2011-08-02
GB2451042A (en) 2009-01-14
SE0850071L (sv) 2008-12-19
HUE036378T2 (hu) 2018-07-30
EP2013619B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
GB2451042A (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals
BRPI0613429A2 (pt) inibidores de histona desacetilase
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
MX2014003153A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
NI200700287A (es) Inhibidores de la fosfolipasa a2 citosolica
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
EP1802766A4 (en) METHOD FOR A GLOBAL COOLING AND FIBRINOLYSIS TEST
BRPI0907656A2 (pt) composto para testar a pureza de cisatracúrio, método para testar a pureza de uma amostra de besilato de cisatracúrio, uso de um composto para testar a pureza de cisatracúrio e processo para preparar compostos para testar a pureza de cisatracúrio
BR112013020883A2 (pt) simulador de separação de fase térmico, e, método para utilizar o simulador de separação de fase térmico
AR060440A1 (es) Agonistas receptores de eritropoietina
ATE541216T1 (de) Fluoreszenztestverfahren
ATE514081T1 (de) T-zellen-testverfahren
ATE487141T1 (de) Hemmung von gasc1
BR112013003898A2 (pt) produto de fabricação, método para determinar se um composto, uma droga, uma molécula pequena ou uma droga de molécula pequena tem qualquer um de, ou um efeito ou uma resposta celular desejado (a) sobre uma célula
MX2012000041A (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
ATE531822T1 (de) Diagnose von prostatakrebs
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO